These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 29027109

  • 1. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
    Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, Robbins S.
    Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H.
    Swiss Med Wkly; 2019 Mar 11; 149():w20026. PubMed ID: 30905063
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
    Connolly MP, Kotsopoulos N, Ustianowski A.
    J Med Econ; 2018 Jan 11; 21(1):19-26. PubMed ID: 28830254
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A.
    World J Gastroenterol; 2019 Mar 21; 25(11):1327-1340. PubMed ID: 30918426
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T, Dumont IP, Heinzow HS, Hutton DW.
    Gastroenterology; 2017 Dec 21; 153(6):1531-1543.e2. PubMed ID: 29074450
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME.
    J Gastroenterol Hepatol; 2016 Apr 21; 31(4):872-82. PubMed ID: 26514998
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
    Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ.
    J Infect Public Health; 2020 Nov 21; 13(11):1715-1723. PubMed ID: 32988769
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH, Ward JW, Sherman KE.
    Clin Gastroenterol Hepatol; 2019 Apr 21; 17(5):930-939.e9. PubMed ID: 30201597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S.
    Scand J Gastroenterol; 2015 Feb 21; 50(2):233-44. PubMed ID: 25515032
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of screening for chronic hepatitis C infection in the United States.
    Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE.
    Clin Infect Dis; 2013 May 21; 56(10):1382-93. PubMed ID: 23392392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.